
Rigel names Anne-Marie Duliege chief medical officer
pharmafile | March 9, 2016 | Appointment | Medical Communications |Â Â Â
Biotech firm Rigel Pharmaceuticals (Nasdaq: RIGL) named Anne-Marie Duliege its chief medical officer, replacing Elliott Grossbard, who is retiring.
Dr Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP), the clinical-stage company said in a statement.
Raul Rodriguez, president and chief executive officer of Rigel, said, “Anne-Marie’s experience overseeing haematology product approvals will be put to immediate use at this crucial stage in our fostamatinib program, and she will play a significant role in the advancement of our entire product pipeline.”
Dr Duliege has extensive experience in the biopharmaceutical industry and has held roles in clinical research and development at Genentech, and Chiron Corporation, and most recently served as chief of strategic development and head of immuno-oncology at ChemoCentryx.
Dr. Duliege received her Doctorate of Medicine and her certification in Pediatrics from Paris Medical School, where she also received an M.S. in Biostatistics, and holds an M.S. in Epidemiology from the Harvard School of Public Health. She is an Adjunct Clinical Assistant Professor at Stanford’s School of Medicine and the Lucile Packard Children’s Hospital. She also serves on the board of CIRM, the California Institute for Regenerative Medicine.
Anjali Shukla






